EGFR Exon 19 (Deletion)

About

Gene context: EGFR

Biomarker Type: Somatic Variant

Present: True

Chromosome: 7

Variant Annotation: Deletion

Exon: 19

Requires Oncogenic: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA